[[link removed]] Ms. Memo: This Week in Women's Rights
April 12, 2023
From the ongoing fight for abortion rights and access, to elections, to the drive for the Equal Rights Amendment, there are a multitude of battles to keep up with. In this weekly roundup, find the absolute need-to-know news for feminists.
Federal Courts in Texas and Washington Release Contradictory Rulings. Abortion Pills Remain on the Market—For Now [[link removed]]
[link removed] [[link removed]]
Doses of mifepristone packages are pictured at Dr. Franz Theards Women’s Reproductive Clinic in Santa Teresa, N.M., on May 7, 2022. (Paul Ratje / The Washington Post via Getty Images)
BY CARRIE N. BAKER | On Friday, April 7, federal judges in both Texas and Washington state issued contradictory rulings on the abortion pill mifepristone.
*
Federal
judge
Matthew
Kacsmaryk
of
the
Northern
District
of
Texas
ruled
that
the
FDA
improperly
approved
mifepristone
andsaid
he
would
void
the
approval
on
April
14.
*
One
hour
later,
fellow
federal
judge
Thomas
O.
Rice
in
the
Eastern
District
of
Washington
issued
an
injunction
blocking
the
FDA
from
“altering
the
status
quo
and
rights
as
it
relates
to
the
availability
of
mifepristone.”
The FDA is now under contradictory federal court orders regarding its approval of mifepristone—with one court saying the FDA approval of mifepristone is invalid, and another saying it must maintain its approval of mifepristone.
“FDA is under one order that says you can do nothing, and another that says in seven days I’m going to require you to vacate the approval of mifepristone,” Glenn Cohen of Harvard Law School told the Associated Press.
The Texas court also ruled that mailing abortion pills is a crime in violation of the 1873 Comstock Act, which prohibited sending obscene materials through the U.S. mail.
The Department of Justice immediately appealed Kacsmaryk’s ruling. Attorney General Merrick Garland said the DOJ “strongly disagrees with the decision. … [which] overturns the FDA’s expert judgment, rendered over two decades ago, that mifepristone is safe and effective. The department will continue to defend the FDA’s decision.”
(Click here to read more) [[link removed]]
Read more
[link removed] [[link removed]] [link removed] [[link removed]]
U.S. Tax Code Disadvantages Single Women, Married Black Couples and Gay Couples the Most. Here’s How [[link removed]] In Wisconsin Supreme Court Election, Abortion Rights Prove Decisive [[link removed]]
[link removed] [[link removed]] [link removed] [[link removed]]
The Truth About the Adoption Option [[link removed]] The Same Groups That Helped Overturn Roe and Attack Abortion Pills Are Also Lobbying Against the ERA [[link removed]]
What we're reading
Because it's hard to keep up with everything going on in the world right now. Here's what we're reading this week:
*
"The
Abortion
Ban
Backlash
Is
Starting
to
Freak
Out
Republicans”
—
New
York
Times
[[link removed]]
*
"Injustice
in
Nashville”
—
Steady
[[link removed]]
[link removed] [[link removed]] Tune in for a new episode of Ms. magazine's podcast, On the Issues with Michele Goodwin on Apple Podcasts [[link removed]] + Spotify [[link removed]] .
In 2022, women voters across the U.S. made their voices heard, demanding access to safe reproductive healthcare. And yet, state legislatures—which purport to represent the people—continue to attack reproductive rights, proposing increasingly restrictive bans on abortion. In the face of these challenges, how can we work towards a government that truly represents us—and protects us?
We hope you'll listen, subscribe, rate and review today!
READ THE REST [[link removed]] | GET THE MAGAZINE [[link removed]] | SUPPORT MS. [[link removed]]
[[link removed]]
[link removed] [[link removed]] [link removed] [[link removed]] [link removed] [[link removed]]
Enjoy this newsletter? Forward to a friend!
Was this email forwarded to you by a friend? Subscribe [[link removed]] .

Ms. Magazine
1600 Wilson Boulevard
Suite 801
Arlington, VA 22209
United States
If you believe you received this message in error or wish to no longer receive email from us, please
unsubscribe: [link removed] .